Karolinska Development AB (publ) (KDEV.ST)
SEK 1.07
(3.5%)
SEK 1.07
(3.5%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.07 Million SEK | 307.7% |
| 2022 | 753 Thousand SEK | -99.4% |
| 2021 | 125.33 Million SEK | 63.68% |
| 2020 | 76.57 Million SEK | -15.56% |
| 2019 | 90.69 Million SEK | -81.04% |
| 2018 | 478.3 Million SEK | 26.14% |
| 2017 | 379.18 Million SEK | -3.87% |
| 2016 | 394.43 Million SEK | 12.95% |
| 2015 | 349.2 Million SEK | 1427.71% |
| 2014 | 22.85 Million SEK | 142.19% |
| 2013 | 9.43 Million SEK | 0.0% |
| 2012 | - SEK | -100.0% |
| 2011 | 2 Million SEK | 0.0% |
| 2010 | 2 Million SEK | 0.0% |
| 2009 | - SEK | 0.0% |
| 2008 | - SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 2.83 Million SEK | -7.69% |
| 2024 Q2 | 2.59 Million SEK | -8.43% |
| 2023 Q1 | 543 Thousand SEK | -27.89% |
| 2023 Q3 | 258 Thousand SEK | -30.27% |
| 2023 Q2 | 370 Thousand SEK | -31.86% |
| 2023 Q4 | 3.07 Million SEK | 1089.92% |
| 2023 FY | 3.07 Million SEK | 307.7% |
| 2022 Q3 | 922 Thousand SEK | -15.49% |
| 2022 Q4 | 753 Thousand SEK | -18.33% |
| 2022 FY | 753 Thousand SEK | -99.4% |
| 2022 Q1 | 1.25 Million SEK | -99.0% |
| 2022 Q2 | 1.09 Million SEK | -13.21% |
| 2021 Q4 | 125.33 Million SEK | 1.49% |
| 2021 FY | 125.33 Million SEK | 63.68% |
| 2021 Q1 | 78.47 Million SEK | 2.48% |
| 2021 Q2 | 79.72 Million SEK | 1.6% |
| 2021 Q3 | 123.49 Million SEK | 54.89% |
| 2020 Q1 | 71.24 Million SEK | -21.45% |
| 2020 Q2 | 71.09 Million SEK | -0.21% |
| 2020 Q3 | 75.33 Million SEK | 5.96% |
| 2020 Q4 | 76.57 Million SEK | 1.65% |
| 2020 FY | 76.57 Million SEK | -15.56% |
| 2019 FY | 90.69 Million SEK | -81.04% |
| 2019 Q2 | 507.11 Million SEK | 2.78% |
| 2019 Q4 | 90.69 Million SEK | -82.07% |
| 2019 Q1 | 493.41 Million SEK | 3.16% |
| 2019 Q3 | 505.81 Million SEK | -0.26% |
| 2018 Q4 | 478.3 Million SEK | 14.97% |
| 2018 FY | 478.3 Million SEK | 26.14% |
| 2018 Q2 | 403.74 Million SEK | 3.14% |
| 2018 Q3 | 416.02 Million SEK | 3.04% |
| 2018 Q1 | 391.46 Million SEK | 3.24% |
| 2017 Q3 | 368.41 Million SEK | 3.04% |
| 2017 Q4 | 379.18 Million SEK | 2.92% |
| 2017 FY | 379.18 Million SEK | -3.87% |
| 2017 Q1 | 346.67 Million SEK | -12.11% |
| 2017 Q2 | 357.55 Million SEK | 3.14% |
| 2016 FY | 394.43 Million SEK | 12.95% |
| 2016 Q1 | 360.51 Million SEK | 3.24% |
| 2016 Q2 | 371.82 Million SEK | 3.14% |
| 2016 Q4 | 394.43 Million SEK | 2.95% |
| 2016 Q3 | 383.12 Million SEK | 3.04% |
| 2015 Q3 | 339.19 Million SEK | 3.04% |
| 2015 Q1 | 309.16 Million SEK | 1252.52% |
| 2015 FY | 349.2 Million SEK | 1427.71% |
| 2015 Q4 | 349.2 Million SEK | 2.95% |
| 2015 Q2 | 329.18 Million SEK | 6.48% |
| 2014 Q4 | 22.85 Million SEK | 93.47% |
| 2014 Q2 | 442 Thousand SEK | -95.72% |
| 2014 Q1 | 10.33 Million SEK | 9.53% |
| 2014 Q3 | 11.81 Million SEK | 2573.08% |
| 2014 FY | 22.85 Million SEK | 142.19% |
| 2013 Q4 | 9.43 Million SEK | 0.0% |
| 2013 Q2 | - SEK | 0.0% |
| 2013 Q1 | - SEK | 0.0% |
| 2013 FY | 9.43 Million SEK | 0.0% |
| 2013 Q3 | - SEK | 0.0% |
| 2012 Q2 | 1.9 Million SEK | -5.0% |
| 2012 Q1 | 2 Million SEK | 0.0% |
| 2012 FY | - SEK | -100.0% |
| 2012 Q4 | - SEK | -100.0% |
| 2012 Q3 | 1.67 Million SEK | -11.84% |
| 2011 FY | 2 Million SEK | 0.0% |
| 2011 Q4 | 2 Million SEK | 0.0% |
| 2010 FY | 2 Million SEK | 0.0% |
| 2009 FY | - SEK | 0.0% |
| 2008 FY | - SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 16.09 Million SEK | 80.928% |
| Ziccum AB (publ) | 857 Thousand SEK | -258.226% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 4.97 Million SEK | 38.341% |
| Sprint Bioscience AB (publ) | - SEK | -Infinity% |
| Mendus AB (publ) | 24.48 Million SEK | 87.463% |
| Genovis AB (publ.) | 79.32 Million SEK | 96.13% |
| Intervacc AB (publ) | 181 Thousand SEK | -1596.133% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.61 Million SEK | 85.105% |
| Active Biotech AB (publ) | 3 Million SEK | -2.333% |
| Magle Chemoswed Holding AB (publ) | 60.3 Million SEK | 94.909% |
| Bio-Works Technologies AB (publ) | - SEK | -Infinity% |
| Aptahem AB (publ) | 5 Million SEK | 38.6% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | - SEK | -Infinity% |
| Saniona AB (publ) | 71.4 Million SEK | 95.701% |
| Lipigon Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Biovica International AB (publ) | 7.82 Million SEK | 60.782% |
| Spago Nanomedical AB (publ) | - SEK | -Infinity% |
| AcouSort AB (publ) | - SEK | -Infinity% |
| Xintela AB (publ) | - SEK | -Infinity% |
| Abliva AB (publ) | 424 Thousand SEK | -624.057% |
| Egetis Therapeutics AB (publ) | 108.6 Million SEK | 97.173% |
| OncoZenge AB (publ) | - SEK | -Infinity% |
| Amniotics AB (publ) | 2.58 Million SEK | -18.992% |
| 2cureX AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | - SEK | -Infinity% |
| Asarina Pharma AB (publ) | 1 Million SEK | -207.0% |
| Calliditas Therapeutics AB (publ) | 979.13 Million SEK | 99.686% |
| Camurus AB (publ) | 24.5 Million SEK | 87.473% |
| Corline Biomedical AB | - SEK | -Infinity% |
| IRLAB Therapeutics AB (publ) | 27.56 Million SEK | 88.863% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | - SEK | -Infinity% |
| Hansa Biopharma AB (publ) | 866.76 Million SEK | 99.646% |
| Cyxone AB (publ) | 858 Thousand SEK | -257.809% |
| ExpreS2ion Biotech Holding AB (publ) | 1.71 Million SEK | -79.427% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | 36.8 Million SEK | 91.659% |
| Elicera Therapeutics AB (publ) | - SEK | -Infinity% |
| Nanologica AB (publ) | 666 Thousand SEK | -360.961% |
| SynAct Pharma AB | 637 Thousand SEK | -381.947% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | 850 Thousand SEK | -261.176% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 1.76 Million SEK | -74.333% |
| BioInvent International AB (publ) | 23.24 Million SEK | 86.792% |
| Alzinova AB (publ) | 800 Thousand SEK | -283.75% |
| Oncopeptides AB (publ) | 106.48 Million SEK | 97.117% |
| Pila Pharma AB (publ) | 773.08 Thousand SEK | -297.113% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | - SEK | -Infinity% |
| Simris Alg AB (publ) | 90.74 Million SEK | 96.617% |
| Diamyd Medical AB (publ) | 30.67 Million SEK | 89.991% |
| Xbrane Biopharma AB (publ) | 231.47 Million SEK | 98.674% |
| Ascelia Pharma AB (publ) | 1.06 Million SEK | -189.35% |
| Diagonal Bio AB (publ) | - SEK | -Infinity% |